Immunomodulatory protein for alleviation and/or treatment of coronavirus diseases
AssigneeMycomagic Biotechnology Co., Ltd.
InventorsTung-Yi Lin, Hsin Yeh, Zhi-Hu Lin
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method for alleviating and/or treating a coronavirus disease in a subject in need thereof, including administering an effective amount of Ganoderma immunomodulatory protein, a recombinant thereof or a fragment thereof to the subject.
Claims15
A method for alleviating and/or treating a SARS-CoV-2 disease in a subject in need thereof, comprising administering an effective amount of Ganoderma immunomodulatory protein to the subject in need thereof, wherein the Ganoderma immunomodulatory protein comprises the amino acid sequence of SEQ ID NO:
- 3.
A method for inhibiting SARS-CoV-2-induced inflammation in a subject in need thereof, comprising administering an effective amount of Ganoderma immunomodulatory protein to the subject in need thereof, wherein the Ganoderma immunomodulatory protein comprises the amino acid sequence of SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.